Olmesartan Milpharm (Olmesartan Medoxomil)

Olmesartan medoxil, the active ingredient in Olmesartan Milpharm, is a angiotensin II receptor blocker presented as an oral tablet for oral use. It is indicated for the treatment of hypertension and for reducing cardiovascular risk in adults. GNH USA supplies Olmesartan Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Milpharm is an ARB that lowers blood pressure by blocking the effects of angiotensin II on the vascular system. - Hypertension: provides sustained reduction of systolic and diastolic blood pressure. - Hypertension with cardiovascular risk: helps lower the incidence of major cardiovascular events. - Hypertension with left ventricular hypertrophy: contributes to stroke risk reduction in patients with this cardiac condition.

Common Side Effects: - Dizziness: mild to moderate light‑headedness, especially after the first dose. - Headache: transient tension‑type headache. - Fatigue: general feeling of tiredness. - Abdominal pain: mild stomach discomfort. - Nasopharyngitis: cold‑like symptoms. - Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway. - Hyperkalemia: elevated serum potassium levels. - Acute renal impairment: sudden decline in kidney function. - Severe hypotension: marked drop in blood pressure causing faintness. - Hepatic dysfunction: abnormal liver enzyme elevations. - Anaphylactic reaction: rare severe allergic response.

Before initiating therapy, consider the following precautions: - Monitor blood pressure: ensure adequate control and avoid excessive lowering. - Assess renal function: check serum creatinine and eGFR regularly. - Check serum potassium: especially when combined with potassium‑sparing agents. - Avoid use in pregnancy: teratogenic risk; discontinue if pregnancy is confirmed. - Use caution in hepatic impairment: dose adjustment may be required. - Store at ambient temperature: keep in the original pack, protect from moisture.

Olmesartan may interact with several medicines, requiring attention to the nature of the interaction. Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal dysfunction and hypotension. - Potassium‑sparing diuretics or supplements: heightened risk of hyperkalemia. - ACE inhibitors: combined use can lead to excessive potassium elevation and renal impairment. - NSAIDs (e.g., ibuprofen, naproxen): may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: additive blood‑pressure lowering effect. - Lithium: olmesartan can raise lithium concentrations, risking toxicity. - Other antihypertensives (beta‑blockers, calcium channel blockers): may enhance hypotensive response. - CYP450 inhibitors (e.g., ketoconazole): may modestly increase olmesartan plasma levels.